FMC Corp
FMC
9.09
+0.06
+0.66%
FMC Corp
US · FMC
#3036 by market cap
Listed 1970
9.09
+0.06
+0.66%
Live - 5344 symbols - heartbeat 348s ago
· 2026-10-08 05:47
Pre-market
9.30
+2.31%
After-hours
9.10
+0.11%
- Market cap
- 1.41B
- P/E (TTM)i
- -0.41
- P/Bi
- 0.86
- EPSi
- -17.88
- Div yieldi
- 9.02%
- 52W posi
- 3%
Reader sentiment
Are you bullish or bearish on FMC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.33, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -18.34% YoY
Margins
- Gross margin
- 37.00%
- Operating margin
- 9.57%
- Net margin
- -64.60%
Key ratios & quality
- Enterprise valuei
- 4.93B
- Altman Z-Scorei
- 1.33
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.29B | 4.61B | 4.64B | 5.05B | 5.80B | 4.49B | 4.25B | 3.47B |
| Gross profit | 1.88B | 2.08B | 2.05B | 2.16B | 2.33B | 1.83B | 1.65B | 1.28B |
| Selling & admin expenses | 790.00M | 792.90M | 729.70M | 714.10M | 775.20M | 734.30M | 644.60M | 684.90M |
| Research & development | 287.70M | 298.10M | 287.90M | 304.70M | 314.20M | 328.80M | 278.00M | 266.10M |
| Operating profit | 802.10M | 992.60M | 1.03B | 1.14B | 1.24B | 767.90M | 726.30M | 332.00M |
| Pretax profit | 608.40M | 655.00M | 731.00M | 897.80M | 983.90M | 300.20M | 252.50M | -1.89B |
| Tax | 70.80M | 111.50M | 151.20M | 92.50M | 145.20M | -1.12B | -150.90M | 314.20M |
| Net profit | 511.50M | 480.20M | 551.50M | 737.10M | 741.50M | 1.32B | 341.60M | -2.24B |
| Basic EPS | 4 | 4 | 4 | 6 | 6 | 11 | 3 | -18 |
| Diluted EPS | 3.69 | 3.62 | 4.23 | 5.73 | 5.81 | 10.53 | 2.72 | -17.88 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 791.40M | 1.05B | 542.20M | 1.08B | 758.60M | 867.10M |
| Gross profit | 316.70M | 406.30M | 128.90M | 431.10M | 246.60M | 342.10M |
| Selling & admin expenses | 172.00M | 176.80M | 167.40M | 168.70M | 185.10M | 179.10M |
| Research & development | 68.70M | 66.40M | 63.30M | 67.70M | 65.50M | 60.40M |
| Operating profit | 76.00M | 163.10M | -101.80M | 194.70M | -4.00M | 102.60M |
| Pretax profit | 4.90M | 58.80M | -466.00M | -1.48B | -149.20M | -194.30M |
| Tax | 13.50M | 14.40M | 82.20M | 204.10M | 112.10M | -1.50M |
| Net profit | -15.60M | 67.80M | -568.60M | -1.72B | -281.20M | -186.30M |
| Basic EPS | 0 | 1 | -5 | -14 | -2 | -1 |
| Diluted EPS | -0.12 | 0.53 | -4.52 | -13.74 | -2.25 | -1.49 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.03B | 4.07B | 4.38B | 5.05B | 5.44B | 5.13B | 4.96B | 4.96B |
| Cash & ST investments | 134.40M | 339.10M | 568.90M | 516.80M | 572.00M | 302.40M | 357.30M | 584.50M |
| Inventory | 1.03B | 1.02B | 1.10B | 1.52B | 1.65B | 1.72B | 1.20B | 1.22B |
| Total assets | 9.97B | 9.87B | 10.19B | 10.67B | 11.17B | 11.93B | 11.65B | 9.69B |
| Total current liabilities | 2.99B | 2.72B | 2.83B | 3.52B | 3.80B | 3.38B | 3.02B | 3.76B |
| Short-term debt | 547.70M | 259.20M | 363.90M | 464.30M | 562.80M | 958.40M | 361.90M | 1.33B |
| Long-term debt | 2.15B | 3.03B | 2.93B | 2.73B | 2.73B | 3.02B | 3.03B | 2.77B |
| Total liabilities | 6,763,900,000.00 | 7,311,300,000.00 | 7,202,200,000.00 | 7,529,400,000.00 | 7,770,400,000.00 | 7,492,800,000.00 | 7,144,500,000.00 | 7,588,300,000.00 |
| Total equity | 3.21B | 2.56B | 2.98B | 3.14B | 3.40B | 4.43B | 4.51B | 2.10B |
| Retained earnings | 4.33B | 4.19B | 4.51B | 5.09B | 5.56B | 6.59B | 6.64B | 4.17B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.08B | 5.47B | 5.57B | 4.96B | 4.90B | 4.73B |
| Cash & ST investments | 315.30M | 438.20M | 497.70M | 584.50M | 390.90M | 476.60M |
| Inventory | 1.37B | 1.40B | 1.38B | 1.22B | 1.24B | 1.21B |
| Total assets | 11.80B | 12.30B | 12.08B | 9.69B | 9.42B | 9.14B |
| Total current liabilities | 3.31B | 3.57B | 3.99B | 3.76B | 3.81B | 2.38B |
| Short-term debt | 975.80M | 893.30M | 1.27B | 1.33B | 1.76B | 326.30M |
| Long-term debt | 3.03B | 3.27B | 3.27B | 2.77B | 2.77B | 3.95B |
| Total liabilities | 7,389,300,000.00 | 7,869,000,000.00 | 8,278,000,000.00 | 7,588,300,000.00 | 7,569,600,000.00 | 7,483,700,000.00 |
| Total equity | 4.41B | 4.43B | 3.80B | 2.10B | 1.85B | 1.66B |
| Retained earnings | 6.55B | 6.54B | 5.90B | 4.17B | 3.88B | 3.68B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 368.40M | 488.50M | 647.80M | 820.10M | 582.40M | -386.40M | 671.10M | -80.20M |
| Depreciation & amortization | 150.20M | 150.10M | 162.70M | 170.90M | 169.40M | 184.30M | 176.30M | 173.60M |
| Free cash flow | 285.40M | 394.60M | 580.60M | 720.00M | 440.10M | -520.30M | 603.20M | -176.50M |
| Dividends paid | -89.20M | -210.30M | -228.50M | -247.20M | -267.50M | -290.50M | -290.60M | -291.30M |
| Stock buybacks / issuance | 167.50M | -365.50M | -33.70M | -400.10M | -99.50M | -75.90M | -2.10M | -1.60M |
| Ending cash balance | 134.40M | 339.10M | 568.90M | 516.80M | 572.00M | 302.40M | 357.30M | 584.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -558.30M | 49.50M | -208.20M | 636.80M | -616.60M | 344.40M |
| Depreciation & amortization | 43.70M | 43.40M | 43.40M | 43.10M | 42.00M | 41.10M |
| Free cash flow | -589.90M | 34.50M | -231.90M | 610.80M | -633.20M | 339.10M |
| Dividends paid | -72.70M | -72.80M | -72.90M | -72.90M | -10.00M | -10.20M |
| Stock buybacks / issuance | -1.20M | 0 | -300.00K | -100.00K | -900.00K | -300.00K |
| Ending cash balance | 315.30M | 438.20M | 497.70M | 584.50M | 390.90M | 476.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 17.21 | 16.84 | 20.03 | 24.51 | 22.93 | 33.86 | 7.64 | -68.30 |
| ROA %i | 5.21 | 4.80 | 5.48 | 7.08 | 6.76 | 11.42 | 2.88 | -20.99 |
| ROIC %i | 10.49 | 10.25 | 10.81 | 13.35 | 13.12 | 19.52 | 6.25 | -28.93 |
| 5-year avg ROE %i | 20.03 | 19.37 | 17.63 | 20.29 | 20.19 | 23.52 | 21.68 | 4.01 |
| EBIT margin %i | 18.58 | 17.69 | 18.98 | 20.31 | 19.57 | 11.98 | 11.50 | -47.50 |
| FCF / sales %i | 4.48 | 8.56 | 12.51 | 14.27 | 7.58 | -- | 14.21 | -- |
| Current ratioi | 1.35 | 1.50 | 1.55 | 1.44 | 1.43 | 1.52 | 1.64 | 1.32 |
| Quick ratioi | 0.83 | 1.03 | 1.09 | 0.95 | 0.95 | 0.96 | 1.17 | 0.78 |
| Debt / assetsi | 27.17 | 34.98 | 33.81 | 31.26 | 30.66 | 34.42 | 30.00 | 43.34 |
| LT debt / equityi | 69.28 | 126.14 | 104.01 | 91.92 | 84.72 | 71.34 | 69.84 | 138.42 |
| Interest coveragei | 6.53 | 5.08 | 5.82 | 7.82 | 7.48 | 2.27 | 2.07 | -6.87 |
| Revenue CAGR (3Y) %i | 19.82 | 22.00 | 22.40 | 5.59 | 7.97 | -1.13 | -5.59 | -15.77 |
| Net income CAGR (3Y) %i | 0.89 | 31.68 | 1.02 | 13.78 | 15.55 | 33.74 | -22.74 | -- |
| FCF CAGR (3Y) %i | -- | -0.99 | 25.01 | 36.13 | 3.70 | -- | -5.73 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 7.53 | 2.22 | -12.69 | -68.30 | -80.78 | -91.47 |
| ROA %i | 2.75 | 0.82 | -4.38 | -20.99 | -23.62 | -25.74 |
| ROIC %i | 5.80 | 3.06 | -4.27 | -28.93 | -31.93 | -35.93 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 11.50 | 12.96 | 0.06 | -47.50 | -52.01 | -62.41 |
| FCF / sales %i | 4.82 | -- | -- | -- | -- | 2.61 |
| Current ratioi | 1.54 | 1.53 | 1.40 | 1.32 | 1.29 | 1.99 |
| Quick ratioi | 0.97 | 0.98 | 0.71 | 0.78 | 0.69 | 1.07 |
| Debt / assetsi | 33.93 | 33.86 | 37.60 | 43.34 | 48.13 | 46.81 |
| LT debt / equityi | 69.09 | 74.37 | 86.66 | 138.42 | 152.06 | 241.59 |
| Interest coveragei | 2.11 | 2.42 | 0.01 | -6.87 | -7.02 | -7.67 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Insecticides is the largest reported line at 48.84% of revenue, across 5 reported segments.
- Herbicides follows at 36.70%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Insecticides48.84%
Herbicides36.70%
Fungicides10.19%
Plant Health4.19%
Quote time 2026-10-08 05:47:53 · For reference only, not investment advice and not tailored to your situation.